News

New research suggests people with SM may be able to tolerate antibiotics and NSAIDs when testing is done under careful medical supervision.

A case of systemic mastocytosis in which recurrent vertebral fractures were the primary symptom was recently reported.

HT-KIT, a precision antisense oligonucleotide (ASO) therapy targeting KIT-driven malignancies and SM, has shown promising results in trials.

Bezuclastinib received Breakthrough Therapy Designation from the FDA for certain patients with nonadvanced SM.

Researchers found that individuals with nonadvanced SM without skin involvement are at a heightened risk of experiencing anaphylaxis.

New research suggests the gut microbiome may one day play a role in disease management for systemic mastocytosis.

October 20 is International Mastocytosis and Mast Cell Diseases Awareness Day, a day dedicated to showing support and building community.

Researchers found reassuring safety patterns in people with moderate to severe allergies following COVID-19 vaccination.

A new study found that almonds are now a leading cause of tree nut–induced anaphylaxis in adults, despite traditionally been seen as low-risk.

A rare case of SM associated with a skin lymphoma was recently reported, and is the only known case of the lymphoma occurring with BMM.